PMID- 30538548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 10
DP  - 2018
TI  - U94/rep of human herpesvirus 6 inhibits proliferation, invasion, and angiogenesis 
      of glioma.
PG  - 5991-6001
LID - 10.2147/CMAR.S177777 [doi]
AB  - PURPOSE: We previously found the involvement of human herpesvirus 6 (HHV-6) 
      infection in the pathogenesis of glioma. U94/rep, encoded by HHV-6, has been 
      identified to play a vital role in viral gene expression and latency. Recent 
      studies have shown its inhibition of angiogenesis and tumorigenesis in 
      endothelial cells and prostate cancer cell line PC3, respectively. Here, we aimed 
      to investigate the role of U94/rep in the development and progression of glioma. 
      PATIENTS AND METHODS: A total of 20 glioma tissues with positive HHV-6 infection 
      were used for detection of U94/rep. MTT, soft agar, propidium iodide staining, 
      wound healing, Transwell, and chick embryo chorioallantoic membrane assays were 
      applied for evaluation of glioma cells' proliferation, colony formation, cell 
      cycle, migration, invasion, and angiogenesis, respectively. RESULTS: U94/rep 
      transcripts could be detected in 11 out of 20 glioma tissues with positive HHV-6 
      infection. Furthermore, MTT and soft agar assays revealed that overexpression of 
      U94/rep inhibited glioma cell proliferation and colony formation, which may be 
      attributed to the cell cycle arrest at S phase induced by U94/rep. Further 
      analysis demonstrated that U94/rep inhibited glioma cells' migration and invasion 
      and ex vivo angiogenesis. Reduced expression of proangiogenic factors, vascular 
      endothelial growth factor and basic fibroblast growth factor, and type IV 
      collagenases, MMP-2 and MMP-9, was detected in cells overexpressing U94/rep. 
      These decreased factors may undermine glioma cell migration, invasion, and 
      angiogenesis. CONCLUSION: Our results demonstrated that U94/rep could inhibit 
      malignant phenotypes of glioma cells, indicating that it is a potential target 
      for therapeutic intervention.
FAU - Gu, Bin
AU  - Gu B
AD  - Department of Neurosurgery, Zhongda Hospital, School of Medicine, Southeast 
      University, Nanjing, China.
FAU - Li, Lingyun
AU  - Li L
AD  - Department of Developmental Genetics, Nanjing Medical University, Nanjing, China.
FAU - Li, Meng
AU  - Li M
AD  - Department of Neurosurgery, Suqian First Hospital, Suqian, China.
FAU - Wang, Jinfeng
AU  - Wang J
AD  - Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, 
      China.
FAU - Zhang, Guofeng
AU  - Zhang G
AD  - Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, 
      China.
FAU - Yao, Kun
AU  - Yao K
AD  - Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, 
      China.
FAU - Wang, Shizhi
AU  - Wang S
AD  - Key Laboratory of Environmental Medicine Engineering, Ministry of Education, 
      School of Public Health, Southeast University, Nanjing, China, 
      shizhiwang2009@seu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20181120
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6254986
OTO - NOTNLM
OT  - HHV-6
OT  - U94/rep
OT  - glioma
OT  - tumorigenesis
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/12/13 06:00
MHDA- 2018/12/13 06:01
PMCR- 2018/11/20
CRDT- 2018/12/13 06:00
PHST- 2018/12/13 06:00 [entrez]
PHST- 2018/12/13 06:00 [pubmed]
PHST- 2018/12/13 06:01 [medline]
PHST- 2018/11/20 00:00 [pmc-release]
AID - cmar-10-5991 [pii]
AID - 10.2147/CMAR.S177777 [doi]
PST - epublish
SO  - Cancer Manag Res. 2018 Nov 20;10:5991-6001. doi: 10.2147/CMAR.S177777. 
      eCollection 2018.